SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Oliver, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oliver, M. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Prevention of Ventricular Fibrillation During Acute Myocardial Ischemia: Control of Free Fatty Acids

M. F. Oliver, MD, FRCP, FRSE

12 Narrow Street, London E14 8DH, UK

Fatal ventricular fibrillation is a common complication of acute coronary syndromes. Effective preventive measures are not available. Immediate restriction of free fatty acid availability should optimize ischemic myocardial metabolism, reduce ventricular vulnerability, and increase glucose utilization. Rapid inhibition of lipoprotein lipase activity will achieve this. The clinical effects of antilipolytic treatment require further study.

Key Words: ventricular fibrillation • free fatty acids • myocardial ischemia • lipolysis

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 6, No. 3, 213-217 (2001)
DOI: 10.1177/107424840100600301
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
S. R. Smith and P. W. F. Wilson
Free Fatty acids and atherosclerosis--guilty or innocent?
J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2506 - 2508.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Fraser, Z. Gao, M. J. Ozeck, and L. Belardinelli
N-[3-(R)-Tetrahydrofuranyl]-6-aminopurine Riboside, an A1 Adenosine Receptor Agonist, Antagonizes Catecholamine-Induced Lipolysis without Cardiovascular Effects in Awake Rats
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 225 - 231.
[Abstract] [Full Text]


Advertisement